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Abstract De novo artificial chromosomes expressing
genes have been generated in human embryonic stem
cells (hESc) and are maintained following differentia-
tion into other cell types. Human artificial chromosomes
(HAC) are small, functional, extrachromosomal ele-
ments, which behave as normal chromosomes in human
cells. De novo HAC are generated following delivery of
alpha satellite DNA into target cells. HAC are charac-
terized by high levels of mitotic stability and are used as
models to study centromere formation and chromosome
organisation. They are successful and effective as gene
expression vectors since they remain autonomous and
can accommodate larger genes and regulatory regions
for long-term expression studies in cells unlike other
viral gene delivery vectors currently used. Transferring
the essential DNA sequences for HAC formation intact
across the cell membrane has been challenging for a
number of years. A highly efficient delivery system
based on HSV-1 amplicons has been used to target
DNA directly to the ES cell nucleus and HAC stably
generated in human embryonic stem cells (hESc) at high
frequency. HAC were detected using an improved pro-
tocol for hESc chromosome harvesting, which consis-
tently produced high-quality metaphase spreads that
could routinely detect HAC in hESc. In tumour cells,
the input DNA often integrated in the host chromo-
somes, but in the host ES genome, it remained intact.
The hESc containing the HAC formed embryoid bodies,
generated teratoma in mice, and differentiated into neu-
ronal cells where the HAC were maintained. The HAC
structure and chromatin composition was similar to the
endogenous hESc chromosomes. This review will dis-
cuss the technological advances in HAC vector delivery
using HSV-1 amplicons and the improvements in the
identification of de novo HAC in hESc.
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Abbreviations
AAV Adeno-associated virus
FISH Fluorescence in situ hybridization
HAC Human artificial chromosome
hESc Human embryonic stem cells
HSV-1 Herpes simplex virus type 1
HPRT Hypoxanthine phosphoribosyltransferase
Introduction
De novo human artificial chromosomes (HAC) are
small, extrachromosomal elements that contain a func-
tional centromere, enabling their correct replication and
segregation as stable normal chromosomes in human
cells (Kouprina et al. 2014; Grimes and Monaco
2005), together with the endogenous chromosomes.
De novo HAC are generated by introducing specific
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sequences such as α-satellite (alphoid) DNA into eu-
karyotic cells. The essential requirement for a functional
centromere formation in HAC is α-satellite DNA, con-
taining higher-order repeat sequences and a centromere
protein B binding sequence (CENP-B box) (Bergmann
et al. 2012).
By mechanisms not yet elucidated, the cell is able to
recognise the transgenic DNA as centromeric and seed
the deposition of specific protein/epigenetic markers on
the exogenous molecules, leading to the formation of a
fully active centromere, thus transforming the episomal
vector into a full-fledged artificial chromosome (Grimes
and Monaco 2005). In human cells, autonomous HAC
are characterised by high mitotic stability (Grimes and
Monaco 2005; Moralli et al. 2009), unlike other viral
vectors which integrate into the host chromosome and
may result in insertional mutagenesis (Baum 2007). As
there is no limit on the size of the DNA fragments that
can be incorporated into HAC, they represent ideal
vectors for the delivery of large genomic DNA regions
containing genes and their corresponding regulatory
elements. HAC containing the entire human genomic
hypoxanthine phosphoribosyltransferase (HPRT) region
fully complemented the HPRT deficiency in cultured
human fibrosarcoma HT1080 cells (Mejía et al. 2001).
The de novo HAC structure was relatively simple com-
pared to normal chromosomes (Mejía et al. 2001;
Moralli et al. 2009, 2013) and allowed easy characteri-
sation of their composition and chromatin environment.
Known methods for the delivery of large pieces of
DNA are inefficient, often resulting in DNA shearing
and degradation, which is a major obstacle in develop-
ing a HAC expression system in different cell types.
Current methods of introducing DNA into cells include
the use of lipofecting agents, electroporation and viral
and non-viral vectors. Each of these methods shares the
problem that only small pieces of DNA can be put into
cells without the DNA being damaged. Large DNA
fragments have very low transfection efficiencies or
break up when entering cells using current methods.
This has made it very difficult in the past to get suffi-
ciently large pieces of DNA into cells to form a HAC. In
order to use a HAC for gene therapy, the efficiency of
delivery of existing methods needs to be improved.
Most gene expression studies in human embryonic
stem cells (hESc) utilise lentiviral, adenoviral and
adeno-associated (AAV) viral vectors for gene delivery.
However, lentiviral vectors integrate randomly at multi-
ple sites within the host genome leading to insertional
mutagenesis, and although adenoviral vectors remain
episomal, silencing post-transduction may occur.
Another disadvantage is that the capacity of AAV and
lentiviral vectors is limited to approximately 5 and 10 kb
of DNA, respectively.
The herpes simplex virus type 1 (HSV-1)-based
amplicon system offers enormous potential as a versatile
tool for gene delivery and has several unique features
that distinguish it from rest of the viral vector systems
and chemical-mediated gene transfer methods. It can
accommodate and deliver up to 152 kb of exogenous
DNA into the mammalian cells (Saeki et al. 2003;
Wade-Martins et al. 2001). Construction of the amplicon
DNAvector is simple and flexible. The amplicon DNA
does not integrate into the host chromosomes, thus
reducing the risk of insertional mutagenesis. The head-
to-tail, rolling-circle DNA replication mechanism of
HSV-1 also allows amplification of amplicon plasmid
as concatemers leading to increased copy number of
transgenes and consequently their expression. Most
genes in the HSV-1 viral genome are not essential for
virus replication and therefore, can be deleted without
affecting the virus production from the cultured cells.
The lack of viral genes and the availability of amplicon
production in a helper virus-free manner results in lim-
ited immunogenic and cytotoxic effects. Most impor-
tantly, the HSV-1 amplicon can transduce a wide variety
of cell types across a wide range of species, including
dividing and quiescent cells.
Generating HSV-1 amplicons
The HAC vectors are firstly retrofitted with the HSV-1
origin of replication and packaging signal (Fig. 1).
Infectious particles are then produced by co-
transfecting, into the permissive cells such as African
green monkey kidney Vero 2-2 cells, (a) the desired
amplicon DNA (containing the transgene, the HSV
pac signal and HSV oriS), (b) the fHSVΔpacΔ27 0+
vector containing the complete HSV-1 genome save for
the deletion of the pac sequence and the essential gene
ICP27, and (c) an ICP27 expressing plasmid such as
pEBHICP27 (Saeki et al. 2003) (Fig. 2).
Helper functions for the amplification and
packaging/cleavage of amplicon DNA into HSV-1 vi-
rions are supplied in trans by fHSVΔpacΔ27 0+ and
pEBHICP27. However, fHSVΔpacΔ27 0+ itself can-
not be packaged because it lacks the packaging signal,
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Fig. 1 Assembly of HSV-1
amplicon HAC vectors. A large
BAC, carrying alpha satellite and/
or transgenes, is retrofitted with
the HSV-1 necessary elements via
LoxP-Cre recombination with a
smaller plasmid carrying the
HSV-1 origin of replication and
packaging signal
Fig. 2 Production of infectious particles. The HSV-1 amplicon
HAC vector is transfected into helper cells along with the whole
HSV-1 genome (lacking the ICP27 gene and the packaging signal)
and a small plasmid expressing the essential HSV-1 protein ICP27.
The cell assembles the HSV-1 capsids and packages the HSV-1
amplicon HAC vector
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the ICP27 gene and HSV-1 origin of replication.
Moreover, its size has been increased by the addition
of stuffer elements so that the whole construct no longer
fits into the HSV virion, thus further reducing the risk of
generating replication-competent helper viruses. The
HSV-1 amplicon system, therefore, provides a safe and
effective mechanism for gene transfer, as amplicons
infect the target cells, but lack the components for
generating the wild-type virus.
The HSV-1 amplicon DNA can accommodate one or
more transgene cassettes as long as its total size does not
exceed ∼152 kb. Upon provision of HSV helper func-
tions in trans, the amplicon plasmid undergoes head-to-
tail rolling circle replication and results in concatemers
of DNA leading to a total size of ∼152 kb which is then
cleaved at the pac signal and packaged into HSV virions
(Fig. 1).
The infectious particles are then used to transduce the
target cell. The transgenic material is carried directly to
the nucleus, intact (Saeki et al. 2003; Wade-Martins
et al. 2001). This feature of the HSV-1 amplicon deliv-
ery system is especially important for the generation of
human artificial chromosomes and has allowed us to
obtain direct HAC formation in human embryonic stem
cells for the first time.
Establishing HAC in human embryonic stem cells
The generation of HAC in hESc and iPS cells is an
essential step to gene expression and gene therapy stud-
ies. Cells obtained from a patient may be reprogrammed
to form iPS cells, then modified ex vivo with a HAC
vector containing the desired gene and reintroduced into
the patient. hESc could be differentiated into
immunoglobulin-producing cells, which could prove
useful in vaccine production. The HAC generated in
our laboratory and others, have to date been obtained
in tumour-derived or immortalised cell lines, such as the
human fibrosarcoma cell line HT1080. Before HAC can
become fully viable vectors for gene expression studies
and potentially gene therapy, it is necessary to study
their behaviour in cells that have normal genetic back-
grounds such as hESc that can be propagated indefinite-
ly in vitro and can be differentiated in a range of differ-
ent cell types.
In our study, we assembled HSV-1 amplicon tech-
nology HAC input vectors carrying reporter genes
(Mandegar et al. 2011).We routinely obtained infectious
particles suspensions with titres of 108 amplicon/ml.
The vectors were delivered to the hESc cell lines
HUES-2 and HUES-10 (Cowan et al. 2004) and the
results compared to similar experiments in the human
fibrosarcomaHT1080 cells, which are highly efficient at
HAC formation (Grimes and Monaco 2005). The trans-
duction efficiency using HSV-1 amplicons is high, rang-
ing from 27 to 40% in hESc (Mandegar et al. 2011) and
up to 70 % in HT1080 cells (Moralli et al. 2006).
Following G418 selection, several independent clones
can be obtained from each vector in both hESc and
HT1080 cells.
An improved technique for analysing embryonic
stem cells by FISH
In standard HAC generation experiments, clones are
expanded to at least the 10-cm dish stage, before chro-
mosomes are harvested and subjected to fluorescence in
situ hybridization (FISH) to determine if the cells con-
tain HACs or integrations. Thus, the karyotypic analysis
of a large number of hESc clones can be very time-
consuming and expensive. For this reason, the develop-
ment of an improved harvesting technique, which al-
lows to obtain high-quality metaphase spreads from six-
well dishes, proved especially useful for our studies
(Moralli et al. 2011). This method relies on overnight
incubation with a low dose of nocodazole as synchro-
nizing agent. This increases the mitotic index by tenfold,
while maintaining a good chromosome structure. The
cells are swelled by treatment in a buffered hypotonic,
which dramatically improves chromosome spreading.
The quality of the resulting metaphase suspension is
such that they can be easily analysed by FISH or
MFISH (Fig. 3).
Characterisation of HAC in hESc
In our studies, hESc clones were analysed by FISH with
HAC-specific probes (Fig. 4) to determine if the input
vector had integrated randomly into the host cell ge-
nome or if had formed a HAC able to segregate inde-
pendently. While in HT1080, the majority of clones
contained integrations and HAC, whereas in the hESc
clones, the input DNA had formed HAC in a large
percentage of cells and there was no integrated DNA
present (Mandegar et al. 2011).
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The analysis of the hESc HAC with antibodies
against essential centromeric proteins (CENP C)
showed that all the HAC had formed a true cen-
tromere. When grown in the absence of selection,
the HAC were mitotically stable, displaying a
daily loss rate of 0.03–0.24 %. Furthermore, im-
munostaining and RT-PCR analysis of pluripotency
markers (Oct4, Sox2, Nanog, TRA-1-60) indicated
that the cells derived from the HAC clones
remained pluripotent (Mandegar et al. 2011). The
pluripotency of the cells was further confirmed
following directed differentiation of HAC-
containing cells into neuronal type cells and the
development of teratomas with the three germ layers
following the formation assay. Importantly, the HACwere
maintained in the neuronal cells following differentiation,
as shown by FISH with specific probes. Although show-
ing some variability, HAC gene expression was sustained
over time. Compared to transfection, the HSV-1 amplicon
provided highly efficient delivery of small and large DNA
segments to HUES-2 cells, and neither transfection nor
the HSV-1 amplicon technique was toxic to HUES-2
cells, as shown by measuring the average growth rate
post-transduction (Mandegar et al. 2011).
Conclusion
The HSV-1 amplicon technology is a highly efficient
delivery method based on transferring exogenous DNA
packaged in HSV-1 amplicons into cells. The amplicons
efficiently deliver large DNA containing genes within
high-capacity human artificial chromosome vectors into
Fig. 3 MFISH on HUES10 hESc metaphase spread, obtained with an improved chromosome harvesting procedure
Fig. 4 FISH onHAC containing hESc. The metaphase spread has
been hybridised with a 17alpha satellite probe (red signal) identi-
fying the HAC (arrow), along with the endogenous chromosomes
17. The small inset show the DAPI staining of the HAC, as a black
and white picture
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human embryonic stem cells and generate gene express-
ing HAC in hESc cell lines. The HAC are stable and
sustain long-term gene expression. The lack of integrat-
ed DNA in hESc following HSV-1 delivery compared to
integrated DNA following delivery in cultured cells is a
significant difference and will lead to further work on
understanding the mechanism of HAC generation in
human cells. The differences in genome stability be-
tween stem and tumour cells indicate that HAC will be
important in gene therapy strategies for monitoring
chromosome stability in different cell types. HAC vec-
tors are a viable alternative to gene delivery with viral
vectors in hESc with the aim of developing a HAC-
based system for the delivery of therapeutic genes reg-
ulated with tissue-specific promoters to human target
cells for ex vivo treatment. The development of ex vivo
strategies for gene therapy of inherited genetic disorders
and addressing problems in the areas of cancer, aging
and metabolic disorders will be key targets for HAC
therapy.
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